KCNB2

Summary

KCNB2 (potassium voltage-gated channel subfamily B member 2, HGNC:6232) is a protein-coding gene on chromosome 8q21.11, encoding Potassium voltage-gated channel subfamily B member 2 (Q92953). Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and smooth muscle cells.

Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shab-related subfamily. This member is a delayed rectifier potassium channel. The gene is expressed in gastrointestinal smooth muscle cells.

Source: NCBI Gene 9312 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Strong, GenCC)
• GWAS associations: 10
• Clinical variants (ClinVar): 120 total — 1 pathogenic, 1 likely-pathogenic
• Regional missense constraint (gnomAD): 1 of 4 regions constrained (≈15% of expected missense variation)
• GTEx eGene: eQTL in 10 tissues, sQTL in 1 (q < 0.05)
• Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.35 (moderately constrained)
• MANE Select transcript: NM_004770

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6232
Approved symbol	KCNB2
Name	potassium voltage-gated channel subfamily B member 2
Location	8q21.11
Locus type	gene with protein product
Status	Approved
Aliases	Kv2.2
Ensembl gene	ENSG00000182674
Ensembl biotype	protein_coding
OMIM	607738
Entrez	9312

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

MANE Select: ENST00000523207

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1

ENST00000523207, ENST00001135721

RefSeq mRNA: 1 — MANE Select: NM_004770 NM_004770

CCDS: CCDS6209

Canonical transcript exons

ENST00000523207 — 3 exons

Exon	Start	End
ENSE00002091325	72567642	72568313
ENSE00002093880	72935935	72938349
ENSE00002128095	72537225	72537885

Expression profiles

Bgee: expression breadth broad, 94 present calls, max score 83.07.

FANTOM5 (CAGE): breadth broad, TPM avg 1.1287 / max 198.8279, expressed in 245 samples.

Highest expression (Bgee): paraflocculus, middle frontal gyrus, endometrium epithelium, buccal mucosa cell, male germ line stem cell (sensu Vertebrata) in testis.

Genetic regulation across tissues (GTEx eQTL / sQTL)

KCNB2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 10 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

11 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Artery Aorta	eqtl	4.2e-16	+0.43	8:72563624:G:A
Nerve Tibial	eqtl	2.6e-10	-0.32	8:72674166:A:G
Artery Tibial	eqtl	1.1e-05	+0.17	8:72557405:ACTTTT:A
Brain Nucleus accumbens basal ganglia	eqtl	3.1e-05	-0.31	8:72530963:G:T
Spleen	eqtl	4.3e-05	-0.37	8:72898211:G:C
Esophagus Mucosa	eqtl	1.4e-03	-0.35	8:73186557:A:C
Brain Anterior cingulate cortex BA24	eqtl	8.2e-03	-0.13	8:72949514:CTTG:C
Brain Frontal Cortex BA9	eqtl	1.2e-02	-0.21	8:73369313:G:T
Testis	sqtl	2.4e-02	+0.34	8:72106942:T:C
Adipose Subcutaneous	eqtl	2.6e-02	-0.26	8:72960199:T:C
Pituitary	eqtl	4.0e-02	-0.17	8:71621537:C:T

FANTOM5 promoters

8 alternative TSS:

Promoter ID	TPM avg	Samples expressed
89353	0.3583	125
89357	0.3077	110
89356	0.1440	64
89354	0.1171	67
89355	0.0921	54
89359	0.0665	21
89358	0.0267	10
89360	0.0163	8

Top tissues by expression

showing 100 of 261 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
paraflocculus	UBERON:0005351	83.07	gold quality
middle frontal gyrus	UBERON:0002702	82.58	silver quality
endometrium epithelium	UBERON:0004811	81.70	gold quality
buccal mucosa cell	CL:0002336	80.62	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.85	silver quality
Brodmann (1909) area 10	UBERON:0013541	77.52	gold quality
islet of Langerhans	UBERON:0000006	77.51	gold quality
cortical plate	UBERON:0005343	77.01	gold quality
type B pancreatic cell	CL:0000169	74.87	gold quality
olfactory bulb	UBERON:0002264	74.72	gold quality
ganglionic eminence	UBERON:0004023	73.55	gold quality
prefrontal cortex	UBERON:0000451	69.94	gold quality
cerebellar vermis	UBERON:0004720	68.40	gold quality
hair follicle	UBERON:0002073	68.32	gold quality
tongue squamous epithelium	UBERON:0006919	67.43	gold quality
mucosa of paranasal sinus	UBERON:0005030	67.08	gold quality
thymus	UBERON:0002370	66.50	gold quality
frontal cortex	UBERON:0001870	66.45	gold quality
Brodmann (1909) area 23	UBERON:0013554	66.17	gold quality
ventricular zone	UBERON:0003053	65.98	gold quality
neocortex	UBERON:0001950	65.39	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	65.10	gold quality
quadriceps femoris	UBERON:0001377	64.98	gold quality
vastus lateralis	UBERON:0001379	64.93	gold quality
diaphragm	UBERON:0001103	64.89	gold quality
Brodmann (1909) area 9	UBERON:0013540	64.85	gold quality
pancreatic ductal cell	CL:0002079	64.83	silver quality
entorhinal cortex	UBERON:0002728	64.55	gold quality
middle temporal gyrus	UBERON:0002771	63.90	silver quality
embryo	UBERON:0000922	63.87	gold quality
cerebral cortex	UBERON:0000956	63.83	gold quality
superior frontal gyrus	UBERON:0002661	63.64	gold quality
Brodmann (1909) area 46	UBERON:0006483	63.63	silver quality
orbitofrontal cortex	UBERON:0004167	62.76	silver quality
endothelial cell	CL:0000115	62.49	silver quality
right frontal lobe	UBERON:0002810	62.30	gold quality
trachea	UBERON:0003126	61.52	gold quality
cingulate cortex	UBERON:0003027	61.42	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	61.40	gold quality
mucosa of stomach	UBERON:0001199	61.34	gold quality
CA1 field of hippocampus	UBERON:0003881	61.31	gold quality
vena cava	UBERON:0004087	61.29	gold quality
anterior cingulate cortex	UBERON:0009835	61.23	gold quality
postcentral gyrus	UBERON:0002581	60.58	gold quality
primary visual cortex	UBERON:0002436	60.44	gold quality
parietal lobe	UBERON:0001872	59.87	gold quality
triceps brachii	UBERON:0001509	59.67	gold quality
occipital lobe	UBERON:0002021	59.57	gold quality
gluteal muscle	UBERON:0002000	59.49	gold quality
telencephalon	UBERON:0001893	59.04	gold quality
epithelium of nasopharynx	UBERON:0001951	58.96	gold quality
dorsal plus ventral thalamus	UBERON:0001897	58.75	gold quality
forebrain	UBERON:0001890	58.39	gold quality
mucosa of urinary bladder	UBERON:0001259	58.27	gold quality
tibialis anterior	UBERON:0001385	58.17	silver quality
layer of synovial tissue	UBERON:0007616	58.13	gold quality
nasal cavity epithelium	UBERON:0005384	58.07	gold quality
ventral tegmental area	UBERON:0002691	58.03	gold quality
deltoid	UBERON:0001476	58.00	gold quality
gingival epithelium	UBERON:0001949	57.09	gold quality
saphenous vein	UBERON:0007318	56.83	gold quality
tongue	UBERON:0001723	56.80	gold quality
substantia nigra pars compacta	UBERON:0001965	56.59	gold quality
inferior vagus X ganglion	UBERON:0005363	56.58	gold quality
superior vestibular nucleus	UBERON:0007227	56.53	gold quality
Ammon’s horn	UBERON:0001954	56.39	gold quality
body of tongue	UBERON:0011876	56.38	gold quality
superior surface of tongue	UBERON:0007371	56.34	gold quality
cervix epithelium	UBERON:0004801	56.24	gold quality
pericardium	UBERON:0002407	56.15	gold quality
subthalamic nucleus	UBERON:0001906	56.12	gold quality
pharyngeal mucosa	UBERON:0000355	56.06	gold quality
medulla oblongata	UBERON:0001896	55.96	gold quality
synovial joint	UBERON:0002217	55.92	gold quality
parotid gland	UBERON:0001831	55.81	gold quality
oviduct epithelium	UBERON:0004804	55.80	gold quality
nipple	UBERON:0002030	55.78	gold quality
pylorus	UBERON:0001166	55.77	gold quality
epithelial cell of pancreas	CL:0000083	55.74	gold quality
temporal lobe	UBERON:0001871	55.67	gold quality
cardia of stomach	UBERON:0001162	55.60	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	55.50	gold quality
penis	UBERON:0000989	55.48	gold quality
pons	UBERON:0000988	55.45	gold quality
left ventricle myocardium	UBERON:0006566	55.36	gold quality
substantia nigra pars reticulata	UBERON:0001966	55.16	gold quality
lateral nuclear group of thalamus	UBERON:0002736	55.09	gold quality
lateral globus pallidus	UBERON:0002476	54.88	gold quality
spleen	UBERON:0002106	54.69	gold quality
brain	UBERON:0000955	54.59	gold quality
sural nerve	UBERON:0015488	54.56	gold quality
pituitary gland	UBERON:0000007	54.35	gold quality
pancreas	UBERON:0001264	54.25	gold quality
renal medulla	UBERON:0000362	54.24	gold quality
hypothalamus	UBERON:0001898	54.24	gold quality
central nervous system	UBERON:0001017	54.14	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	54.05	gold quality
colonic epithelium	UBERON:0000397	53.48	gold quality
male germ cell	CL:0000015	53.06	gold quality
gingiva	UBERON:0001828	52.25	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-ANND-2	yes	2380.14
E-HCAD-30	yes	466.67
E-HCAD-35	yes	64.85
E-GEOD-137537	yes	3.75
E-ANND-3	yes	3.11

HPA expression

RNA tissue specificity: Tissue enhanced

47 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Olfactory bulb	tissue	22.3
Cerebral cortex	tissue	15.6
Somatosensory cortex	tissue	15.6
Occipital cortex	tissue	15.1
Hippocampal formation	tissue	14.9
Entorhinal cortex	tissue	14.9
Motor cortex	tissue	14.8
Prefrontal cortex	tissue	14.6
Cingulate cortex	tissue	13.7
Temporal cortex	tissue	13.0
Retrosplenial cortex	tissue	12.7
Insular cortex	tissue	11.8
Postcentral gyrus	tissue	11.3
Thalamus	tissue	10.2
Superior colliculi	tissue	9.8
Midbrain	tissue	9.7
Pons	tissue	9.6
Hypothalamus	tissue	6.9
Substantia nigra	tissue	6.6
Hippocampus	tissue	6.4
Locus coeruleus	tissue	6.3
Amygdala	tissue	6.2
Periaqueductal gray	tissue	5.4
Septum	tissue	4.6
Ventral pallidum	tissue	4.5
Medulla oblongata	tissue	4.4
Retina	tissue	4.2
Basal ganglia	tissue	3.1
Nucleus accumbens	tissue	3.0
Putamen	tissue	2.9
Spleen	tissue	2.2
Spinal cord	tissue	1.8
Corpus callosum	tissue	1.3
Pituitary gland	tissue	1.0
Cerebellum	tissue	0.8
Thymus	tissue	0.8
Pancreas	tissue	0.5
Choroid plexus	tissue	0.5
Stomach 1	tissue	0.4
Fallopian tube	tissue	0.4
Testis	tissue	0.3
Small intestine	tissue	0.3
Adrenal gland	tissue	0.3
Duodenum	tissue	0.2
Adipose tissue	tissue	0.1
Esophagus	tissue	0.1
Tonsil	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Arcuate nucleus (13.2), Entorhinal gyrus (13.0), Periaquaductal grey, anterior (12.4), Olfactory tubercle (12.0), Stria terminalis, bed nucleus (11.7).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting KCNB2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

30 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-4325	99.49	72.20	1342
HSA-MIR-548G-3P	99.48	68.67	2159
HSA-MIR-19A-5P	99.36	66.93	1675
HSA-MIR-19B-1-5P	99.36	67.07	1669
HSA-MIR-19B-2-5P	99.36	67.07	1669
HSA-MIR-501-3P	99.33	66.12	651
HSA-MIR-502-3P	99.33	66.12	651
HSA-MIR-130A-5P	99.33	70.26	2623
HSA-MIR-1206	99.30	69.32	1016
HSA-MIR-491-3P	98.88	68.86	1224
HSA-MIR-4659A-5P	98.03	66.42	819
HSA-MIR-4659B-5P	98.03	66.84	979
HSA-MIR-5087	98.01	69.09	965
HSA-MIR-22-5P	97.67	68.92	1355
HSA-MIR-5000-5P	97.40	66.11	1055

Functional genomics

gnomAD constraint: pLI 1, LOEUF 0.354, missense Z 3.83 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000523207 splits into 4 regions with different missense tolerance; 1 is missense-constrained (≈15% of the expected missense variation). Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
8:72,567,735–72,567,870	62 / 54.8	1.13	no
8:72,567,871–72,936,251	163 / 314.4	0.52	no
8:72,936,252–72,936,664	44 / 167.6	0.26	yes (p 1.3e-21)
8:72,936,665–72,938,088	559 / 588.4	0.95	no

Literature-anchored findings (GeneRIF, showing 6)

• stromatoxin-1 -sensitive KV2-containing channels are expressed in detrusor smooth muscle (DSM); they control DSM excitability, intracellular Ca2+ levels, and myogenic and nerve-evoked contractions (PMID:22422395)
• The rs2128158 in KCNB2 showed significant associations with MaxDrinks. (PMID:23953852)
• Five de novo mutations were identified in four genes (SCNN1A, KCNJ16, KCNB2, and KCNT1) in three Brugada syndrome patients (PMID:25339316)
• Kv2.1, but not Kv2.2 (KCNB2), forms clusters of 6-12 tetrameric channels at the plasma membrane and facilitates insulin exocytosis (PMID:28607108)
• Kv2 channel-AMIGO beta-subunit assembly modulates both channel function and cell adhesion molecule surface trafficking. (PMID:34137443)
• Protein Kinase C Controls the Excitability of Cortical Pyramidal Neurons by Regulating Kv2.2 Channel Activity. (PMID:34542799)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	kcnb2a	ENSDARG00000038862
danio_rerio	kcnb2b	ENSDARG00000088842

Paralogs (31): KCNG1 (ENSG00000026559), KCNQ1 (ENSG00000053918), KCNQ2 (ENSG00000075043), KCND1 (ENSG00000102057), KCNA7 (ENSG00000104848), KCNA1 (ENSG00000111262), KCNC4 (ENSG00000116396), KCNQ4 (ENSG00000117013), KCNS1 (ENSG00000124134), KCNC1 (ENSG00000129159), KCNA5 (ENSG00000130037), KCNC3 (ENSG00000131398), KCNA10 (ENSG00000143105), KCNA6 (ENSG00000151079), KCNS2 (ENSG00000156486), KCNB1 (ENSG00000158445), KCNF1 (ENSG00000162975), KCNV1 (ENSG00000164794), KCNC2 (ENSG00000166006), KCNV2 (ENSG00000168263), KCNG4 (ENSG00000168418), KCNS3 (ENSG00000170745), KCNG3 (ENSG00000171126), KCND3 (ENSG00000171385), KCNA3 (ENSG00000177272), KCNA2 (ENSG00000177301), KCNG2 (ENSG00000178342), KCNA4 (ENSG00000182255), KCNQ3 (ENSG00000184156), KCND2 (ENSG00000184408), KCNQ5 (ENSG00000185760)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:99632) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 9 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased hematocrit	1
weakness	1
hyperactivity	1
decreased locomotor activity	1
decreased exploration in new environment	1
abnormal sleep pattern	1
decreased erythrocyte cell number	1
increased circulating alanine transaminase level	1
increased circulating bilirubin level	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Streptomyces coelicolor A3(2)	P0A333	100.0%	Diamond
Streptomyces lividans	P0A334	100.0%	Diamond
Mus musculus	P63141	100.0%	Diamond
Rattus norvegicus	P63142	100.0%	Diamond
Pongo abelii	Q5RC10	100.0%	Diamond
Macaca fascicularis	Q9GKU7	100.0%	Diamond
Macaca mulatta	A4K2T1	99.8%	Diamond
Chlorocebus aethiops	A4K2Y2	99.8%	Diamond
Pan troglodytes	A4K2N8	99.4%	Diamond
Oryctolagus cuniculus	P59995	99.4%	Diamond
Mustela putorius furo	Q8HYZ1	99.4%	Diamond
Papio anubis	A4K2M4	99.2%	Diamond
Gorilla gorilla gorilla	A4K2R3	99.2%	Diamond
Mesocricetus auratus	Q60565	99.0%	Diamond
Colobus guereza	A4K2P6	98.9%	Diamond
Canis lupus familiaris	Q28293	98.8%	Diamond
Aotus nancymaae	A4K2W6	98.1%	Diamond
Saimiri boliviensis boliviensis	A4K2X4	98.1%	Diamond
Sus scrofa	O18868	97.3%	Diamond
Bos taurus	Q0P583	96.8%	Diamond
Otolemur garnettii	A4K2Q6	93.4%	Diamond
Lemur catta	A4K2S2	93.4%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
KCNB2-AS1	ncRNA	139355243
TERF1	protein-coding	7013
SBSPON	protein-coding	157869

Protein

Protein identifiers

Potassium voltage-gated channel subfamily B member 2 — Q92953 (reviewed: Q92953)

Alternative names: Voltage-gated potassium channel subunit Kv2.2

All UniProt accessions (1): Q92953

UniProt curated annotations — full annotation on UniProt →

Function. Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and smooth muscle cells. Channels open or close in response to the voltage difference across the membrane, letting potassium ions pass in accordance with their electrochemical gradient. Homotetrameric channels mediate a delayed-rectifier voltage-dependent outward potassium current that display rapid activation and slow inactivation in response to membrane depolarization. Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNB1; channel properties depend on the type of alpha subunits that are part of the channel. Can also form functional heterotetrameric channels with other alpha subunits that are non-conducting when expressed alone, such as KCNS1 and KCNS2, creating a functionally diverse range of channel complexes. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Contributes to the delayed-rectifier voltage-gated potassium current in cortical pyramidal neurons and smooth muscle cells.

Subunit / interactions. Homotetramer or heterotetramer with KCNB1. Heterotetramer with KCNS1 and KCNS2. Interacts (via phosphorylated FFAT motif) with VAPA and VAPB.

Subcellular location. Cell membrane. Perikaryon. Cell projection. Dendrite.

Post-translational modifications. Phosphorylated. Phosphorylation at Ser-608 of the FFAT motif activates interaction with MOSPD2, VAPA and VAPB.

Activity regulation. Inhibited by quinine at micromolar levels. Modestly sensitive to millimolar levels of tetraethylammonium (TEA) and 4-aminopyridine (4-AP).

Domain organisation. The transmembrane segment S4 functions as a voltage-sensor and is characterized by a series of positively charged amino acids at every third position. Channel opening and closing is effected by a conformation change that affects the position and orientation of the voltage-sensor paddle formed by S3 and S4 within the membrane. A transmembrane electric field that is positive inside would push the positively charged S4 segment outwards, thereby opening the pore, while a field that is negative inside would pull the S4 segment inwards and close the pore. Changes in the position and orientation of S4 are then transmitted to the activation gate formed by the inner helix bundle via the S4-S5 linker region. The FFAT motif is involved in the interaction with VAPA and VAPB and its phosphorylation regulates these interactions.

Similarity. Belongs to the potassium channel family. B (Shab) (TC 1.A.1.2) subfamily. Kv2.2/KCNB2 sub-subfamily.

RefSeq proteins (1): NP_004761* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR003131	T1-type_BTB	Domain
IPR003968	K_chnl_volt-dep_Kv	Family
IPR003973	K_chnl_volt-dep_Kv2	Family
IPR005821	Ion_trans_dom	Domain
IPR005826	K_chnl_volt-dep_Kv2.2	Family
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR027359	Volt_channel_dom_sf	Homologous_superfamily
IPR028325	VG_K_chnl	Family

Pfam: PF00520, PF02214, PF03521

Catalyzed reactions (Rhea)

• K(+)(in) = K(+)(out) (RHEA:29463)

UniProt features (39 total): topological domain 8, region of interest 7, transmembrane region 6, compositionally biased region 6, intramembrane region 2, short sequence motif 2, modified residue 2, sequence variant 2, sequence conflict 2, chain 1, glycosylation site 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92953-F1	61.23	0.29

Human Protein Atlas

Protein class: Transporters, Transporter channels and pores, Voltage-gated ion channels, Voltage-Gated Potassium Channels, Predicted membrane proteins, FDA approved drug targets, Small molecule drugs, UniProt - Evidence at transcript level

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): plasma membrane; midbody; nucleoli

Antibody reliability (HPA): IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2)

Type	Positions
Phosphoserine	448, 608

Glycosylation sites (1)

Type	Positions
N-linked (glcnac…) asparagine	287

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 3; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

3 pathways:

ID	Pathway	Evidence
R-HSA-1296072	Voltage gated Potassium channels	curated
R-HSA-112316	Neuronal System	—
R-HSA-1296071	Potassium Channels	—

MSigDB gene sets: 111 (showing top): GOBP_POTASSIUM_ION_TRANSPORT, RNGTGGGC_UNKNOWN, AAGCAAT_MIR137, REACTOME_VOLTAGE_GATED_POTASSIUM_CHANNELS, REACTOME_POTASSIUM_CHANNELS, ENK_UV_RESPONSE_KERATINOCYTE_UP, GOBP_REGULATION_OF_SMOOTH_MUSCLE_CONTRACTION, AP2_Q3, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_REGULATION_OF_MUSCLE_CONTRACTION, SOX9_B1, GOBP_MUSCLE_CONTRACTION, GATA1_01, MODULE_99

GO Biological Process (9): action potential (GO:0001508), potassium ion transport (GO:0006813), regulation of smooth muscle contraction (GO:0006940), protein homooligomerization (GO:0051260), potassium ion transmembrane transport (GO:0071805), protein localization to plasma membrane (GO:0072659), monoatomic ion transport (GO:0006811), monoatomic ion transmembrane transport (GO:0034220), transmembrane transport (GO:0055085)

GO Molecular Function (7): delayed rectifier potassium channel activity (GO:0005251), potassium channel regulator activity (GO:0015459), protein heterodimerization activity (GO:0046982), monoatomic ion channel activity (GO:0005216), voltage-gated potassium channel activity (GO:0005249), potassium channel activity (GO:0005267), protein binding (GO:0005515)

GO Cellular Component (8): plasma membrane (GO:0005886), voltage-gated potassium channel complex (GO:0008076), membrane (GO:0016020), dendrite (GO:0030425), neuronal cell body membrane (GO:0032809), neuronal cell body (GO:0043025), perikaryon (GO:0043204), monoatomic ion channel complex (GO:0034702)

Reactome top-level categories

2 top-level categories:

Category	Pathways
Potassium Channels	1
Neuronal System	1

GO top-level categories

35 GO namespaces:

Category	Terms
transport	2
potassium channel activity	2
cellular anatomical structure	2
neuronal cell body	2
regulation of membrane potential	1
metal ion transport	1
regulation of muscle contraction	1
smooth muscle contraction	1
protein complex oligomerization	1
potassium ion transport	1
monoatomic cation transmembrane transport	1
protein localization to membrane	1
protein localization to cell periphery	1
monoatomic ion transport	1
transmembrane transport	1
cellular process	1
voltage-gated potassium channel activity	1
ion channel regulator activity	1
protein dimerization activity	1
monoatomic ion transmembrane transporter activity	1
channel activity	1
voltage-gated monoatomic cation channel activity	1
monoatomic cation channel activity	1
potassium ion transmembrane transporter activity	1
binding	1
membrane	1
cell periphery	1
potassium channel complex	1
plasma membrane protein complex	1
neuron projection	1
dendritic tree	1
cell body membrane	1
somatodendritic compartment	1
cell body	1
transmembrane transporter complex	1

Protein interactions and networks

STRING

showing 15 of 1,256 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KCNB2	KCNAB3	O43448	770
KCNB2	CA4	P22748	557
KCNB2	KCNE1	P15382	546
KCNB2	KCNH5	Q8NCM2	462
KCNB2	KCNAB2	Q13303	462
KCNB2	KCNN2	Q9H2S1	431
KCNB2	KCNAB1	Q14722	426
KCNB2	KCNH8	Q96L42	425
KCNB2	KCNN1	Q92952	417
KCNB2	SERTM1	A2A2V5	411
KCNB2	KCNB1	Q14721	407
KCNB2	CA10	Q9NS85	405
KCNB2	CACNG4	Q9UBN1	399
KCNB2	KCNH3	Q9ULD8	392
KCNB2	CACNB2	Q08289	384

IntAct

Human interaction partners of KCNB2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

3 partners by confidence:

Partner	Interaction type	MIscore	Records
GRB2	physical association	0.400	1
KCNG4	physical association	0.400	1
SCRIB	physical association	0.400	1

BioGRID (74 interactions; top human partners by supporting records): KCNG4 (Affinity Capture-MS; 3 records), KCNB1 (Two-hybrid; 2 records), KCNG3 (Two-hybrid; 2 records), KCNS3 (Affinity Capture-MS; 2 records), LAMP1 (Proximity Label-MS; 2 records), VAPA (Protein-peptide; 2 records), AMIGO1 (Affinity Capture-Western), AMIGO2 (Affinity Capture-Western), AMIGO3 (Affinity Capture-Western), ANPEP (Proximity Label-MS), B3GAT1 (Proximity Label-MS), BCAP31 (Proximity Label-MS), BET1 (Proximity Label-MS), CACNA1C (Co-localization), CACNA1D (Co-localization)

SIGNOR signaling

2 signaling interactions:

A	Effect	B	Mechanism
KCNB2	“up-regulates quantity”	VAPB	relocalization
KCNB2	“up-regulates quantity”	VAPA	relocalization

Protein complexes (CORUM) (2)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

2 complexes by size:

Complex	Subunits	Members
★ KCNV2-KCNB2 complex	2	KCNB2, KCNV2
★ KCNV1-KCNB2 complex	2	KCNB2, KCNV1

Disease & clinical

Genetic variants

Variant evidence for KCNB2: 120 ClinVar records (2 pathogenic / likely pathogenic); 10 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

120 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	94
Likely benign	13
Benign	8

Top pathogenic / likely-pathogenic (2)

Showing all 2 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
4680923	NM_004770.3(KCNB2):c.1141A>G (p.Thr381Ala)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
4850836	NM_004770.3(KCNB2):c.911G>A (p.Arg304Gln)	Pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore KCNB2’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 14 predictions of 1,486):

Position(s)	Effect	Δscore	Sites
8:72621217	acceptor_gain	1.0000
8:72621423	donor_gain	1.0000
8:72858781	donor_gain	1.0000
8:72935933–72935934	acceptor_loss	1.0000	5
8:72776479	acceptor_gain	0.9900
8:72935934	acceptor_loss	0.9900
8:72537678	donor_gain	0.9800
8:72570586	acceptor_gain	0.9800
8:72605911	acceptor_gain	0.9800
8:72621418	donor_gain	0.9800

AlphaMissense

2,491 missense substitutions predicted likely pathogenic (of 6,033 scored), across 475 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M379	9	0.990	1.000
M114	9	0.987	0.999
M148	9	0.950	0.998
M110	9	0.947	0.999
M111	9	0.935	0.996
M344	9	0.934	1.000
M306	9	0.889	0.998
H109	8	1.000	1.000
D90	8	0.999	1.000
D270	8	0.999	0.999
F420	8	0.999	1.000
F96	8	0.998	1.000
F341	8	0.998	1.000
D386	8	0.998	1.000
F89	8	0.997	1.000
F119	8	0.997	1.000
F349	8	0.997	1.000
H46	8	0.996	1.000
F244	8	0.996	1.000
H317	8	0.996	0.999

HPA cancer prognostics

RNA cancer specificity: Not detected

Disease associations

OMIM: gene MIM:607738 | disease phenotypes:

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
neurodevelopmental disorder	Strong	Autosomal dominant	3

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (7 panels, 4 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

7 panels:

Panel	Rating
DDG2P	green
Hypotonic infant	green
Intellectual disability	green
Leukodystrophy, childhood onset	green
Early onset or syndromic epilepsy	amber
Paediatric disorders	amber
Unexplained death in infancy and sudden unexplained death in childhood	amber

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

GWAS associations

10 associations:

Study	Trait	p-value
GCST010988_545	Adult body size	7e-20
GCST007576_244	Chronotype	2e-10
GCST010242_397	HDL cholesterol levels	3e-9
GCST001438_7	Crohn’s disease	2e-8
GCST008529_35	Tea consumption	3e-8
GCST010118_27	Type 2 diabetes	3e-8
GCST000579_56	Cognitive performance	1e-6
GCST000267_4	Multiple sclerosis (age of onset)	3e-6
GCST000110_3	Echocardiographic traits	5e-6
GCST006281_9	Coronary artery disease in type 1 diabetes	6e-6

EFO canonical traits (from GWAS)

7 canonical traits:

EFO ID	Trait name
EFO:0004295	left ventricular function
EFO:0004298	cardiovascular measurement
EFO:0004847	age at onset
EFO:0003926	neuropsychological test
EFO:0008328	chronotype measurement
EFO:0010091	tea consumption measurement
EFO:0004612	high density lipoprotein cholesterol measurement

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2321618 (SINGLE PROTEIN), CHEMBL2362996 (PROTEIN FAMILY)

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: vgic — Voltage-gated potassium channels (K_v)

Most potent curated ligand interactions (7 total), top 7:

Ligand	Action	Affinity	Parameter
GxTx-1E	Gating inhibitor	8.6	pKd
ScTx1	Gating inhibitor	7.7	pIC50
RY796	Gating inhibitor	7.1	pIC50
RY785	Gating inhibitor	6.7	pIC50
quinine	Channel blocker	4.9	pIC50
fampridine	Channel blocker	2.8	pIC50
tetraethylammonium	Channel blocker	2.6	pIC50

Binding affinities (BindingDB)

6 measured of 7 human assays (8 total across all organisms); most potent 6 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
CHEMBL2324356	IC50	100 nM
CHEMBL375083	IC50	2080 nM
N-(2-aminoethyl)-5-chloronaphthalene-1-sulfonamide	IC50	24000 nM	US-11542290: Phenothiazine derivatives and uses thereof
CHEMBL219249	IC50	60200 nM
CHEMBL218975	IC50	67600 nM
CHEMBL386028	IC50	83100 nM

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.82	Ki	0.15	nM	CHEMBL5722941
9.74	IC50	0.18	nM	CHEMBL5722941
7.00	IC50	100	nM	CHEMBL2324356

PubChem BioAssay actives

3 with measured affinity, of 40 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-[(1R,2aS,4S,5aS,8aS,10S,11aR,14aS,16S,17aS,19S,20aS,22S,23aS,25S,26aS,28S,29aS,31R,32aS,35aS,36R,38aS,39S,41aS,42S,44aS,45S,48R,50aS,51S,53aS,54S,56aS,57S,59aS,60S,63S,66S,69S,72S,75S,78S,87R,93S,96S,99S)-17a,20a,23a,53a,63-pentakis(4-aminobutyl)-31-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-carbamimidamido-2-[[(2S)-5-carbamimidamido-2-[[(2S)-1-[(2S)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-16,29a,72,78-tetrakis(2-amino-2-oxoethyl)-14a,26a-bis(3-amino-3-oxopropyl)-2a,38a,66-tribenzyl-28,50a,57-tris[(2S)-butan-2-yl]-4,5a,19,42,45,69-hexakis(3-carbamimidamidopropyl)-51,54-bis(2-carboxyethyl)-56a,99-bis(carboxymethyl)-36-[[(2S,3S)-1-(carboxymethylamino)-3-methyl-1-oxopentan-2-yl]carbamoyl]-39,60-bis[(1R)-1-hydroxyethyl]-75,93-bis(hydroxymethyl)-32a,35a,59a-tris[(4-hydroxyphenyl)methyl]-22-(1H-imidazol-4-ylmethyl)-96-(1H-indol-3-ylmethyl)-41a-methyl-25-(2-methylpropyl)-1a,3,4a,6,7a,9,10a,13a,15,16a,18,19a,21,22a,24,25a,27,28a,30,31a,34a,37a,38,40a,41,43a,44,47,49a,50,52a,53,55a,56,58a,59,61a,62,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-33,34,63a,64a,67a,68a-hexathia-a,2,3a,5,6a,8,9a,12a,14,15a,17,18a,20,21a,23,24a,26,27a,29,30a,33a,36a,37,39a,40,42a,43,46,48a,49,51a,52,54a,55,57a,58,60a,61,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazapentacyclo[85.74.4.448,111.010,14.0144,148]nonahexacontahectan-8a-yl]propanoic acid	2198828: Binding affinity to KV channel (unknown origin) assessed as inhibition constant	ki	0.0001	uM
2-(dimethylamino)-5-(2-methylpropanoylamino)-N-[(1S)-1-phenylethyl]benzamide	726268: Inhibition of voltage-gated K channel 2.2 (unknown origin) by automated patch clamp assay	ic50	0.1000	uM

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, decreases expression	2
bisphenol A	decreases methylation	1
mono-(2-ethylhexyl)phthalate	decreases methylation, increases abundance	1
4-nonylphenol	affects cotreatment, increases expression	1
4-tert-octylphenol	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Copper	affects cotreatment, decreases expression	1
Diethylhexyl Phthalate	decreases methylation, increases abundance	1
Estradiol	affects cotreatment, decreases expression	1
Phthalic Acids	increases methylation	1
Aflatoxin B1	decreases methylation	1
Asbestos, Serpentine	increases methylation	1
tert-Butylhydroperoxide	decreases expression	1

ChEMBL screening assays

23 unique, capped per target: 22 binding, 1 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2328103	Binding	Inhibition of voltage-gated K channel 2.2 (unknown origin) by automated patch clamp assay	Ion channels as therapeutic targets: a drug discovery perspective. — *J Med Chem*
CHEMBL5522525	Toxicity	Inhibition of human K+ channel by automated electrophysiology	Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart Failure. — *J Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 510 trials:

NCT	Phase	Status	Title
NCT04586348	Phase 4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	Phase 4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT00114829	Phase 4	UNKNOWN	Preoperative Assessment of Colon Tumor
NCT00114842	Phase 4	COMPLETED	Magnetic Resonance (MR) Colonography With Fecal Tagging
NCT00114946	Phase 4	TERMINATED	A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
NCT00122720	Phase 4	COMPLETED	The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
NCT00129870	Phase 4	TERMINATED	CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer
NCT00138060	Phase 4	COMPLETED	Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
NCT00216424	Phase 4	TERMINATED	Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma
NCT00327093	Phase 4	TERMINATED	Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
NCT00332943	Phase 4	COMPLETED	MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil
NCT00441311	Phase 4	COMPLETED	Dissemination of Colorectal Cancer Screening to Primary Care Physicians
NCT00460837	Phase 4	WITHDRAWN	Comparison of Bowel Preparation in Virtual Colonoscopy (VC) - Patient Experience
NCT00473980	Phase 4	COMPLETED	Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients
NCT00488904	Phase 4	COMPLETED	Omega-3 Fatty Acids and Postoperative Complications After Colorectal Surgery
NCT00496678	Phase 4	COMPLETED	Trial of Patient Navigation-Activation
NCT00502671	Phase 4	COMPLETED	A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
NCT00559676	Phase 4	COMPLETED	Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
NCT00577031	Phase 4	COMPLETED	OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
NCT00626054	Phase 4	COMPLETED	Comparison of Two Methods of Administration of a PEG Solution
NCT00812864	Phase 4	COMPLETED	Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
NCT00868569	Phase 4	UNKNOWN	Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer
NCT00868816	Phase 4	COMPLETED	Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles
NCT00874406	Phase 4	UNKNOWN	Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
NCT00928928	Phase 4	COMPLETED	Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer
NCT00942461	Phase 4	COMPLETED	Inflammatory Response in Laparoscopic and Open Colectomy
NCT01023633	Phase 4	UNKNOWN	OPTIMOX1 in Chinese mCRC Patients
NCT01271582	Phase 4	UNKNOWN	Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
NCT01315990	Phase 4	UNKNOWN	FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
NCT01493713	Phase 4	COMPLETED	Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
NCT01609660	Phase 4	COMPLETED	Impact of Probiotics on the Intestinal Microbiota
NCT01641458	Phase 4	COMPLETED	Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients
NCT01689792	Phase 4	COMPLETED	A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
NCT01695772	Phase 4	COMPLETED	A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
NCT01695863	Phase 4	COMPLETED	Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
NCT01706822	Phase 4	TERMINATED	Radial Reload Laparoscopic LAR Case Series
NCT01740947	Phase 4	TERMINATED	Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?
NCT01831310	Phase 4	COMPLETED	Nutrition for Colorectal Cancer Patients and Neutrophil Functions
NCT01841294	Phase 4	UNKNOWN	NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery
NCT01959061	Phase 4	UNKNOWN	Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
NCT02032953	Phase 4	UNKNOWN	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia
NCT02567331	Phase 4	COMPLETED	A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer
NCT02575378	Phase 4	UNKNOWN	Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer
NCT02581423	Phase 4	COMPLETED	A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer
NCT02582970	Phase 4	COMPLETED	A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum
NCT03084809	Phase 4	COMPLETED	Chemotherapy Combined With CIK Treating Colon Cancer
NCT03130634	Phase 4	COMPLETED	The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment
NCT03298945	Phase 4	COMPLETED	Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens
NCT03465202	Phase 4	UNKNOWN	Association of Capecitabine Pharmacokinetics and Toxicity With Aging
NCT03564938	Phase 4	COMPLETED	Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
NCT03700411	Phase 4	COMPLETED	Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Cancer Surgery
NCT03700541	Phase 4	COMPLETED	Influence of Opioid Analgesia on Circulating Tumor Cells in Laparoscopic Colorectal Cancer Surgery
NCT03723447	Phase 4	COMPLETED	Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
NCT04074460	Phase 4	COMPLETED	Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study
NCT04281667	Phase 4	ACTIVE_NOT_RECRUITING	Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery
NCT04297423	Phase 4	COMPLETED	Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy
NCT04874207	Phase 4	COMPLETED	Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib
NCT04874883	Phase 4	UNKNOWN	Effect of the Use of Symbiotics in Patients With Colon Cancer
NCT04973007	Phase 4	TERMINATED	Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases
NCT05661357	Phase 4	UNKNOWN	Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for KCNB2 across ~30M SureChEMBL compounds — explore on Sugi Predict.